Recently, the first gene therapy drug, an AAV-based vector carrying a correct copy of the RPE65 gene, was approved by FDA for treating retinal degenerative Leber congenital amaurosis type 2 (LCA2), which is caused by recessive mutations in RPE6528,32–35. Here, RPE65 is linked to Leber congenital amaurosis 2.